Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NVS
NVS logo

NVS News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

NVS News

BioArctic AB Reports Strong Earnings, Positive Outlook for Leqembi Sales

May 20 2026Yahoo Finance

Analysis of Trends in International Stock ETF Investments

May 19 2026Fool

Novo Nordisk Goes All In on Wegovy Global Launch

May 18 2026CNBC

Novartis to Close Wehr Facility by End of 2028

May 06 2026NASDAQ.COM

German Stock Market Hit Hard by New COVID Variant Concerns

May 01 2026CNBC

Latest Developments in the Biotech Sector

Apr 30 2026NASDAQ.COM

Market Volatility Amidst Surging Oil Prices

Apr 30 2026CNBC

AstraZeneca and GSK Q1 Earnings Beat Expectations

Apr 29 2026CNBC

NVS Events

05/31 17:50
Novartis Reports Pluvicto Efficacy Data in Prostate Cancer Treatment
Novartis announced results showing consistent radiographic progression-free survival, rPFS, improvement across key subgroups with Pluvicto plus standard of care compared to SoC alone in PSMA-positive metastatic hormone-sensitive prostate cancer, mHSPC. These PSMAddition data were presented as an oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting. The subgroup analysis evaluated outcomes by disease volume (high or low) and disease presentation. Pluvicto demonstrated a similar rPFS improvement across key subgroups, consistent with the previously reported primary endpoint showing a 28% reduction in the risk of radiographic progression or death. Secondary endpoints for disease progression were also consistent. Together, these data support use of Pluvict as early as PSMA+ metastatic prostate cancer diagnosis.
05/18 16:20
Stocks Open Mixed as Rising Oil Prices Raise Concerns
Stocks finished mixed to start the week as investors continue to watch climbing oil prices while awaiting more developments out of the Middle East. Investors are increasingly worried that inflation is becoming entrenched due to energy prices, persistent fiscal deficits and resilient economic demand. Markets are now pricing in a meaningful possibility that the Federal Reserve could raise rates again later this year instead of cutting them.Of note, President Trump stated in athat he was asked by the leaders of several Middle Eastern nations to hold off a planned military attack on Iran, which was scheduled for tomorrow, but added that he has instructed the U.S. military leadership "to be prepared to go forward with a full, large scale assault of Iran, on a moment's notice, in the event that an acceptable Deal is not reached."Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Dominionand NextEra Energyin an all-stock transactionPublicisLiveRampfor $2.2BFordand EDF Group announced the signing of aTrump plans to announce a "dramatic expansion" of discounted prescription medication offerings available on TrumpRx,A U.S. jury on Monday ruled against Elon Musk in his lawsuit against OpenAI, finding the AI company not liable to the Teslafounder for having allegedly strayed from its original mission to benefit humanity,2. WALL STREET CALLS:F5to Outperform from In Line at Evercore ISIZscalerto Buy at B. RileyCoreWeaveand Nebiuswith lowered Neutral ratings as a new analyst took over coverage at DA DavidsonApplied Materialsto Equal Weight at Morgan StanleySalesforcewith an Underperform at BofA amid structural reset3. AROUND THE WEB:NvidiaCEO Jensen Huang told Bloomberg that it is up to China to decide on AI chips and that he looks forward to China being a more open marketTakedahas been ordered to pay hundreds of millions for violating antitrust law by delaying the generic version of its branded Amitiza drug, Bloomberg saysApple'srevamped Siri may launch in beta, and will have an option to auto-delete chats, Bloomberg reportsPresident Trump said he "should have asked for more" of a stake in Intelon behalf of the U.S. government, Fortune saysVinFast'splanned sale of two Vietnamese factories will allow the company to shed $6.9B in debt and obligations to help assist its path to profitability, Bloomberg says4. MOVERS:Hive Digitalwas higher afteris planning to build a new AI infrastructure facility in the Greater Toronto Area with approximately 320 megawatts of utility capacityCourseraincreased after announcing aServiceNowgained after BofAcoverage of the stock with a Buy ratingDesign Therapeuticswas lower afterRegeneronfell after its Phase 3 trial of fianlimab5. EARNINGS/GUIDANCE:Bradyand raised its guidance for FY26iQiyi, with EPS and revenue lower year-over-yearGossamer Bio, with CEO Faheem Hasnain commenting, "We are executing across multiple fronts at Gossamer"RedCloudreportedand reaffirmed guidance for FY26Baidu, with EPS and revenue lower year-over-yearINDEXES:The Dow rose 159.95, or 0.32%, to 49,686.12, the Nasdaq lost 134.41, or 0.51%, to 26,090.73, and the S&P 500 declined 5.45, or 0.074%, to 7,403.05.

NVS Monitor News

Novartis' Cosentyx Receives FDA Approval for Pediatric Use

Mar 18 2026

Novartis AG hits a 20-day low amid sector rotation

Mar 11 2026

Novartis reports Q4 earnings beat amid cautious outlook

Feb 04 2026

Novartis Expands RLT Manufacturing with New Facility in Florida

Jan 14 2026

Novartis AG reaches 52-week high amid market strength

Jan 06 2026

NVS Earnings Analysis

No Data

No Data

People Also Watch